[go: up one dir, main page]

MX2017016555A - Compuestos inhibidores de la señalizacion de la via de notch. - Google Patents

Compuestos inhibidores de la señalizacion de la via de notch.

Info

Publication number
MX2017016555A
MX2017016555A MX2017016555A MX2017016555A MX2017016555A MX 2017016555 A MX2017016555 A MX 2017016555A MX 2017016555 A MX2017016555 A MX 2017016555A MX 2017016555 A MX2017016555 A MX 2017016555A MX 2017016555 A MX2017016555 A MX 2017016555A
Authority
MX
Mexico
Prior art keywords
notch
signaling
inhibiting compounds
hair cell
auditory hair
Prior art date
Application number
MX2017016555A
Other languages
English (en)
Other versions
MX376082B (es
Inventor
Arthur Hipskind Philip
D Wrobleski Aaron
Zhao Gaiying
Marie Clay Julia
Kumar Patel Bharvin
Edge Albert
C Gill John
Hendrikus Gerardus Vas Es Helmuth
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017016555A publication Critical patent/MX2017016555A/es
Publication of MX376082B publication Critical patent/MX376082B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona compuestos, o una sal farmacéuticamente aceptable de estos y composiciones farmacéuticas que contienen dichos compuestos útiles como un inhibidor de la señalización de la vía Notch para el tratamiento de los cánceres nombrados, pérdida de audición neurosensorial causada por la pérdida de células ciliadas auditivas, e inducción de la generación de células ciliadas auditivas. (ver Fórmulas).
MX2017016555A 2015-07-07 2016-07-01 Compuestos inhibidores de la señalizacion de la via de notch. MX376082B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189393P 2015-07-07 2015-07-07
PCT/US2016/040612 WO2017007702A1 (en) 2015-07-07 2016-07-01 Notch pathway signaling inhibitor compounds

Publications (2)

Publication Number Publication Date
MX2017016555A true MX2017016555A (es) 2018-11-09
MX376082B MX376082B (es) 2025-03-07

Family

ID=56507825

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016555A MX376082B (es) 2015-07-07 2016-07-01 Compuestos inhibidores de la señalizacion de la via de notch.

Country Status (42)

Country Link
US (1) US10450317B2 (es)
EP (1) EP3319967B1 (es)
JP (1) JP6571214B2 (es)
KR (1) KR102078946B1 (es)
CN (1) CN107849054B (es)
AR (1) AR105080A1 (es)
AU (1) AU2016289822B2 (es)
CA (1) CA2987431C (es)
CL (1) CL2018000007A1 (es)
CO (1) CO2018000224A2 (es)
CR (2) CR20220368A (es)
CY (1) CY1122024T1 (es)
DK (1) DK3319967T3 (es)
DO (1) DOP2018000005A (es)
EA (1) EA032634B1 (es)
EC (1) ECSP18000042A (es)
ES (1) ES2735139T3 (es)
HK (1) HK1247187B (es)
HR (1) HRP20191175T1 (es)
HU (1) HUE044666T2 (es)
IL (1) IL255726B (es)
JO (1) JO3491B1 (es)
LT (1) LT3319967T (es)
MA (1) MA42399B1 (es)
MD (1) MD3319967T2 (es)
ME (1) ME03495B (es)
MX (1) MX376082B (es)
MY (1) MY197519A (es)
NZ (1) NZ737322A (es)
PE (1) PE20180412A1 (es)
PH (1) PH12018500047B1 (es)
PL (1) PL3319967T3 (es)
PT (1) PT3319967T (es)
RS (1) RS59115B1 (es)
SI (1) SI3319967T1 (es)
SV (1) SV2017005597A (es)
TN (1) TN2017000495A1 (es)
TR (1) TR201908683T4 (es)
TW (1) TWI625332B (es)
UA (1) UA120539C2 (es)
WO (1) WO2017007702A1 (es)
ZA (1) ZA201707858B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
AR105080A1 (es) 2015-07-07 2017-09-06 Lilly Co Eli Compuestos inhibidores de la señalización de la vía de notch
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US11253193B2 (en) * 2016-11-08 2022-02-22 Cochlear Limited Utilization of vocal acoustic biomarkers for assistive listening device utilization
KR20190098998A (ko) 2016-12-16 2019-08-23 파이프라인 테라퓨틱스, 아이엔씨. 달팽이관 시냅스질환의 치료 방법
TW201838989A (zh) * 2017-03-24 2018-11-01 瑞士商諾華公司 異噁唑羧醯胺化合物及其用途
US11117932B2 (en) * 2018-07-20 2021-09-14 The Hong Kong Polytechnic University Peptides for specific inhibition of Jag 1-Notch 1 pathway
CR20210148A (es) * 2018-09-21 2021-05-18 Novartis Ag Compuestos de isoxazol carboxamida y usos de los mismos
WO2020072602A1 (en) 2018-10-02 2020-04-09 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
WO2020112883A1 (en) * 2018-11-30 2020-06-04 Massachusetts Eye And Ear Infirmary Inhibition of lysine demethylase 1 (lsd1) induces differentiation of hair cells
CA3136424A1 (en) 2019-04-08 2020-10-15 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
WO2021150672A2 (en) * 2020-01-22 2021-07-29 Beth Israel Deaconess Medical Center, Inc. Biomarkers for placenta accreta spectrum (pas) disorders
WO2022158610A1 (en) * 2021-01-20 2022-07-28 Prism BioLab Co., Ltd. Novel bicyclic compounds
WO2023200017A1 (en) * 2022-04-11 2023-10-19 Prism BioLab Co., Ltd. Novel seven-membered ring-fused compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
MX2008012136A (es) 2006-03-27 2008-10-03 Hoffmann La Roche Derivados de malonamida como inhibidores de gama secretasa.
EP2732819B1 (en) 2008-02-07 2019-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
AU2009316264B2 (en) 2008-11-24 2016-09-15 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
WO2012047706A2 (en) 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
AR087107A1 (es) * 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
US8716229B2 (en) 2011-11-09 2014-05-06 Massachusetts Eye & Ear Infirmary Osteoprotegerin in neuroprotection
US20150209367A1 (en) * 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
EP2914724A1 (en) 2012-11-02 2015-09-09 Genesys Research Institute Compositions and methods for auditory therapy
AR105080A1 (es) 2015-07-07 2017-09-06 Lilly Co Eli Compuestos inhibidores de la señalización de la vía de notch
KR20190098998A (ko) * 2016-12-16 2019-08-23 파이프라인 테라퓨틱스, 아이엔씨. 달팽이관 시냅스질환의 치료 방법

Also Published As

Publication number Publication date
DOP2018000005A (es) 2018-10-31
MA42399A (fr) 2018-05-16
US10450317B2 (en) 2019-10-22
HK1247187B (zh) 2020-01-10
CN107849054A (zh) 2018-03-27
TN2017000495A1 (en) 2019-04-12
JO3491B1 (ar) 2020-07-05
MA42399B1 (fr) 2019-08-30
ECSP18000042A (es) 2018-03-31
CR20170598A (es) 2018-03-20
JP2018520157A (ja) 2018-07-26
JP6571214B2 (ja) 2019-09-04
RS59115B1 (sr) 2019-09-30
HRP20191175T1 (hr) 2019-10-04
NZ737322A (en) 2019-05-31
IL255726B (en) 2020-10-29
HUE044666T2 (hu) 2019-11-28
AU2016289822B2 (en) 2018-07-26
TWI625332B (zh) 2018-06-01
US20180148456A1 (en) 2018-05-31
WO2017007702A1 (en) 2017-01-12
PT3319967T (pt) 2019-07-29
AR105080A1 (es) 2017-09-06
TR201908683T4 (tr) 2019-07-22
ES2735139T3 (es) 2019-12-16
SV2017005597A (es) 2019-04-04
KR102078946B1 (ko) 2020-02-19
CA2987431C (en) 2019-11-26
SI3319967T1 (sl) 2019-08-30
CA2987431A1 (en) 2017-01-12
AU2016289822A1 (en) 2017-11-30
PE20180412A1 (es) 2018-03-01
ZA201707858B (en) 2020-01-29
EA032634B1 (ru) 2019-06-28
PL3319967T3 (pl) 2019-10-31
CY1122024T1 (el) 2020-10-14
CR20220368A (es) 2022-08-23
EP3319967A1 (en) 2018-05-16
CN107849054B (zh) 2020-04-28
ME03495B (me) 2020-01-20
MY197519A (en) 2023-06-19
CO2018000224A2 (es) 2018-04-10
LT3319967T (lt) 2019-08-12
EP3319967B1 (en) 2019-05-22
DK3319967T3 (da) 2019-07-22
KR20180011314A (ko) 2018-01-31
MX376082B (es) 2025-03-07
MD3319967T2 (ro) 2019-11-30
PH12018500047B1 (en) 2021-10-06
IL255726A (en) 2018-01-31
TW201712016A (zh) 2017-04-01
CL2018000007A1 (es) 2018-06-29
EA201792478A1 (ru) 2018-06-29
PH12018500047A1 (en) 2018-07-09
UA120539C2 (uk) 2019-12-26

Similar Documents

Publication Publication Date Title
PH12018500047A1 (en) Notch pathway signaling inhibitor compounds
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
JOP20190174B1 (ar) مثبطات jak1 انتقائية
EA201891644A1 (ru) Антибактериальные соединения и их применение
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
NZ712341A (en) A crystalline form of an anxiolytic compound
WO2018211324A8 (en) Prodrugs for the treatment of disease
EA201791596A1 (ru) Пиразоловые соединения
EA201790231A1 (ru) Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза

Legal Events

Date Code Title Description
FG Grant or registration